176 related articles for article (PubMed ID: 18382132)
1. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina.
Ripoll C; Ponce A; Wilson MM; Sharif N; Vides JB; Armoni J; Teuwen DE
Hum Vaccin; 2008; 4(2):121-6. PubMed ID: 18382132
[TBL] [Abstract][Full Text] [Related]
2. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
[TBL] [Abstract][Full Text] [Related]
3. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
4. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
6. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
7. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of the yellow fever vaccine Stamaril®: a 17-year review.
Cottin P; Niedrig M; Domingo C
Expert Rev Vaccines; 2013 Nov; 12(11):1351-68. PubMed ID: 24066727
[TBL] [Abstract][Full Text] [Related]
9. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
10. Adverse events following yellow fever vaccination in immunocompromised persons.
Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
[TBL] [Abstract][Full Text] [Related]
11. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccination: how much is enough?
Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
[TBL] [Abstract][Full Text] [Related]
13. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
[TBL] [Abstract][Full Text] [Related]
14. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
15. Yellow fever vaccine-associated adverse events following extensive immunization in Argentina.
Biscayart C; Carrega ME; Sagradini S; Gentile A; Stecher D; Orduna T; Bentancourt S; Jiménez SG; Flynn LP; Arce GP; Uboldi MA; Bugna L; Morales MA; Digilio C; Fabbri C; Enría D; Diosque M; Vizzotti C
Vaccine; 2014 Mar; 32(11):1266-72. PubMed ID: 24456625
[TBL] [Abstract][Full Text] [Related]
16. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.
Monath TP; Nichols R; Archambault WT; Moore L; Marchesani R; Tian J; Shope RE; Thomas N; Schrader R; Furby D; Bedford P
Am J Trop Med Hyg; 2002 May; 66(5):533-41. PubMed ID: 12201587
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study.
Kernéis S; Launay O; Ancelle T; Iordache L; Naneix-Laroche V; Méchaï F; Fehr T; Leroy JP; Issartel B; Dunand J; van der Vliet D; Wyplosz B; Consigny PH; Hanslik T
Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1522-8. PubMed ID: 23554297
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.
Pistone T; Verdière CH; Receveur MC; Ezzedine K; Lafon ME; Malvy D
Curr HIV Res; 2010 Sep; 8(6):461-6. PubMed ID: 20636276
[TBL] [Abstract][Full Text] [Related]
20. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.
Barrett AD; Monath TP; Barban V; Niedrig M; Teuwen DE
Vaccine; 2007 Apr; 25(15):2758-65. PubMed ID: 17368349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
